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Abstract: Cardiovascular diseases (CVDs) are a group of conditions associated with heart and blood 
vessels and are considered the leading cause of death globally. Coronary heart disease, atheroscle-
rosis, myocardial infarction represents the CVDs. Since CVDs are associated with a series of patho-
physiological conditions with an alarming mortality and morbidity rate, early diagnosis and appro-
priate therapeutic approaches are critical for saving patients’ lives. Conventionally, diagnostic tools 
are employed to detect disease conditions, whereas therapeutic drug candidates are administered 
to mitigate diseases. However, the advent of nanotechnological platforms has revolutionized the 
current understanding of pathophysiology and therapeutic measures. The concept of combinatorial 
therapy using both diagnosis and therapeutics through a single platform is known as theranostics. 
Nano-based theranostics are widely used in cancer detection and treatment, as evident from pre-
clinical and clinical studies. Nanotheranostics have gained considerable attention for the efficient 
management of CVDs. The differential physicochemical properties of engineered nanoparticles 
have been exploited for early diagnosis and therapy of atherosclerosis, myocardial infarction and 
aneurysms. Herein, we provided the information on the evolution of nano-based theranostics to 
detect and treat CVDs such as atherosclerosis, myocardial infarction, and angiogenesis. The review 
also aims to provide novel avenues on how nanotherapeutics’ trending concept could transform 
our conventional diagnostic and therapeutic tools in the near future. 
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1. Introduction 
Since the discovery of antibiotics, a significant development in the biomedical and 
healthcare sectors’ technological interventions has revolutionized the current understand-
ing of disease diagnosis and therapy. In the last few decades, the global healthcare net-
work’s advancement has also provided a platform to protect and maintain human beings’ 
health profiles [1]. However, the world has also witnessed a similar but exponential inci-
dence of a series of infectious and non-communicable diseases (NCDs). Like infectious 
diseases, NCDs also gained considerable attention in the last few decades due to the high 
mortality and morbidity rate. The evolution of cardiovascular diseases (CVDs), respira-
tory ailments, diabetes, and cancer are the most prominent diseases and disorders that 
account for most health consequences and mortality rates in the 21st century. The emer-
gence of NCDs becomes a public health issue owing to its global impact on human health, 
economy and society. NCDs could account for 70% of global death by 2025, as estimated 
by the World Health Organization (WHO), with a significant implication on developing 
countries. Among them, approximately 84% of global death will occur due to the in-
creased incidence of CVDs (48%), cancer (21%), chronic respiratory ailments (12%) and 
diabetes (3%) by 2025 [2]. The world is currently witnessing the high risk of comorbidities 
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in chronic medical conditions, particularly in the patients with CVDs co-occurring with 
the COVID-19 pandemic, thus providing an alarming risk to the healthcare settings. 
CVDs include a collection of several health conditions, including atherosclerosis, car-
diomyopathy, arrhythmia, myocardial infarction, coronary artery disease, aneurysm and 
hypertension. Since CVDs infer the assemblage of several diseased conditions and disor-
ders, the occurrence of CVDs become a severe global trend. The emergence of CVDs poses 
serious health complications resulting in severe implications on any given country’s econ-
omy. As per the data available, approximately 17.7 million people died across the globe 
in 2015 due to the complications associated with CVDs. In this context, it is estimated that 
by 2030, the mortality due to CVDs could rise to 22 million. In this context, the advance-
ment in the technological perspectives could provide an array of therapeutic alternatives 
to minimize the nuisances of chronic diseases and disorders associated with CVDs. How-
ever, the co-occurrence of CVDs and chronic infectious ailments poses a severe challenge 
to the current therapeutic strategies. Immunotherapy, chemotherapy, and other conven-
tional approaches are considered as the frontline warriors to fight against CVDs. The con-
cept of host-directed therapies also gained considerable attention in the last few years for 
their ability to fight against NCDs, particularly CVDs [3]. Though significant work is go-
ing on to develop and/or curate the conventional therapies to improve the healthcare set-
tings in an emergency, these strategies fall short due to one or other limitations [4]. In this 
regard, it is imperative to look for an effective, alternative and exact method for timely 
diagnosis of CVDs followed by effective treatment procedures. The genome-based ap-
proaches are also found to be influential in disease diagnosis and therapy [5]. 
1.1. Theranostics: An Overview 
For the management of any chronic diseases and/or disorders, the foremost im-
portant thing is the early diagnosis of disease progression and based upon the diagnostic 
information, implementing the proper therapeutic measures. In this regard, approxi-
mately two decades ago, a combinatorial modality involving both diagnosis and thera-
peutics came into the limelight. The integrated concept of ‘theranostic’ was derived from 
therapy and diagnostics. The term “theranostics,” coined by John Funkhouser in 2002, 
refers to an assemblage of diagnostic tools and appropriate therapeutic measures under a 
single platform [6,7]. The theranostic tools have provided a customized platform for tar-
get-guided therapy of chronic disease conditions utilizing the diagnostic and therapeutic 
modalities in a single platform. The integrated theranostic approach provided a new di-
mension to overcome the limitations of differential diagnosis and treatment procedures 
[7,8]. The evolution of theranostic strategies centered around the target-specific diagnos-
tics and therapies and critically distinguished the healthy or non-targeted sites from any 
lethal effect [9]. The notable advantages of theranostic approach are low toxicity, selectiv-
ity, target-specificity, and tunability [10]. Several internal markers such as variations in 
pH, compliance of redox reactions, cellular enzymatic level, and response from genetic 
materials are influential in theranostic functional modalities [11]. 
The advent of theranostics has provided a selective platform for transforming con-
ventional therapeutic medicines to personalized and particular treatments, suggesting a 
more holistic strategy to counteract health consequences of chronic health disease’ [12]. 
The concept of theranostics critically expressed its candidature as next-generation person-
alized medicines. It allows a series of sequential steps such as early detection and diagno-
sis of disease, disease prognosis, therapy selection, and monitoring the therapeutic effi-
cacy with high precision selectivity [13]. Since the limitations such as radiation-associated 
health hazards and inference of allergic reactions are associated with radionuclides during 
chemotherapy and nuclear medicines, theranostics could guide the development of next-
generation nuclear drugs [14]. The specificity with which the theranostic modalities inte-
grate the diagnostics and therapeutics through a common platform could lead the scien-
tific community as a mainstream arsenal against chronic diseases and other health ail-
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ments [15]. The theranostic modalities provide a non-invasive platform to diagnose dis-
ease conditions and targeted therapy. This concept received remarkable recognition in the 
fight against infectious diseases, inflammatory disorders, and cancer therapy. 
1.2. Nanotheranostics: An Emerging Trend 
Nanotechnology in biomedicine and healthcare settings has resulted in the paradigm 
shift in understanding the disease prognosis and efficient therapeutic strategies to over-
come chronic health consequences. The nano-based platforms provided a multifaceted 
platform for rapid and early diagnosis of disease progression. Furthermore, they exhib-
ited therapeutic applications, including spatial targeting of therapeutic drug moieties and 
tracking of therapeutic response from the cellular system using different therapeutic mod-
ules such as gene therapy, chemotherapy, photodynamic therapy and photothermal ther-
apy with differential specificity in terms of therapeutic efficacy [16–18] (Figure 1). The 
emerging trend of nanotechnology in biomedical and healthcare settings has revolution-
ized the scientific upliftment of disease diagnosis and therapy with widespread potential. 
The nanotechnology platforms could be highly considered theranostic modules for effec-
tive diagnosis and treatment due to the physicochemical properties such as high surface-
to-volume ratio, tunability, ease of chemical characterization, and surface properties mod-
ification [19]. The concept of ‘nanotheranostics’ is an advanced version of theranostic mo-
dalities with nanomaterials of differential class and physicochemical properties for dis-
ease diagnosis and optimized therapies [20]. The nanotheranostics represent the most ad-
vanced technological intervention with multifaceted functional attributes such as multi-
modal imaging, drug targeting and improved synergistic therapeutics [21]. 
 
Figure 1. Schematic overview of the concept of nanotheranostics which infers the use of engineered nanomaterials for both 
diagnostics and therapeutic modules through a single platform. 
The engineered nanomaterials of differential classes such as magnetic nanoparticles, 
carbon-based nanomaterials, silica-based nanomaterials, metal-based nanoparticles, and 
polymeric nanoparticles exhibited bimodal applications in terms of both diagnostics and 
therapeutic perspectives. In particular, the light-emitting and light-responsive nano-
materials, such as metal-based nanoparticles with high plasmon resonance (HPR), semi-
conductor quantum dots (QDs), organic and polymeric nanomaterials, gained considera-
ble attention as cost-effective and efficient theranostic agents [22]. The unique structural 
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dimension, unique physicochemical properties, ease of functionalization, improved bio-
compatibility, and, most importantly, the broad range of one-photon properties of carbon-
based nanomaterials are considered landmarks characteristics for biomedical applica-
tions. Carbon-based nanomaterials such as carbon nanotubes (CNTs), QDs, graphene ox-
ide (GO) are being exploited as bimodal applications in the field of diagnostics and ther-
apeutics [23]. Apart from carbon-based nanomaterials, polymeric nanoparticles and their 
combination with different nanomaterials have given a new dimension to nanomaterials 
mediated theranostics for multifaceted functional attributes. The exploitation of combina-
torial nanomaterials found to be influential in disease diagnosis and management [24]. 
The chemistry associated with the conjugated polymeric nanoparticles strictly allows mul-
timodal imaging of deeply situated tissues with spatial resolution when used as con-
trasting agents in near-infrared imaging (NIR imaging), two-photon imaging, and photo-
acoustic imaging. Thus, conjugated polymeric nanomaterials were found to be involved 
in the early diagnosis of disease. Besides, these conjugated nanomaterials are also ob-
served to influence therapeutic modalities such as photothermal therapy (PTT) and pho-
todynamic therapy (PDT), which are considered to be influential in non-invasive thera-
peutics of cancer as clinically approved earlier and hence could be instrumental in CVDs 
management [25,26].  
The highly defined and unique physicochemical properties of nanomaterials are be-
ing exploited as prolific contrasting agents, which proves to be instrumental in the early 
detection and diagnosis of disease prognosis. Hence, nanomaterials are considered effec-
tive bioimaging modalities. Nanomaterials are being used as effective contrasting agents 
for various conventional diagnostic tools such as optical imaging, ultrasonography, mag-
netic resonance imaging (MRI), positron emission tomography (PET), photoacoustic to-
mography and computed tomography (CT). Thus, the role of nanomaterials as bioimag-
ing tools has guided the scientific community towards bioimaging-guided therapeutics 
against NCDs [10]. 
The ease of synthesis, unique physicochemical characteristics, and bimodal applica-
tions associated with the nanomaterials provided a unique platform for detecting and re-
defining the therapeutic measures for various chronic healthcare conditions, including 
neurodegenerative diseases Alzheimer’s disease and Parkinson’s disease [15]. The nan-
otheranostic tools received potential consideration for cancer therapy as the modalities 
allowed to detect and diagnose cancer progression through bioimaging techniques and 
provide a novel drug delivery system for systemic and controlled delivery of therapeutic 
agents at the target sites bypassing several cellular barriers [27]. The emergence of nan-
otheranostic modalities has given a new dimension to the concept of personalized nano-
medicines for efficient management of cancer, inflammatory diseases, CVDs, neurodegen-
erative diseases, diabetes and other chronic health ailments [28,29]. As the nan-
otheranostic tools involve differentially exclusive nanomaterials, the functional attributes 
also vary greatly as per the requirement. For example, theranostic nanomedicine could 
exploit various inorganic nanoparticles as effective contrasting agents for multimodal im-
aging. Similarly, the nanotheranostic platforms can also encapsulate a number of thera-
peutic drug moieties and contrasting agents, thus from a single platform, both the bioim-
aging and therapeutic attributes could be considered. In this context, recently spatially 
designed multifunctional co-loaded magnetic nanocapsules (MNCPs) were developed, 
which could be used not only for enhanced bioimaging modalities but also could be in-
strumental in targeted photodynamic therapy [30]. In a recently reported research work, 
it was evident from the spatially designed and fabricated phosphatidylcholine/choles-
terol-based liposome modified by sodium cholate hydrate could be considered as a bi-
modal platform for diagnostics as well as therapeutics [31]. The nanostructures’ tunability 
allows them to load various therapeutic drug moieties, target-specific ligand molecules, 
and specific antibodies for target-oriented functional attributes [32]. 
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2. Recent Trends in Therapies Associated with Cardiovascular Diseases 
Among the notable non-communicable diseases in recent decades, CVDs emerged as 
the most life-threatening disease condition along with cancer in both developed and de-
veloping countries. CVDs are pathophysiological conditions of the cardiovascular system, 
including the blockage of blood vessels, irregular rhythmic function of heart muscles (ar-
rhythmias), myocardial infractions, dilated cardiomyopathy, etc. CVDs are estimated to 
contribute to the highest percentage of mortalities by the year 2025 among the NCDs. As 
per the records received in the year 2017, CVDs are responsible for 17.7 million deaths 
worldwide, which accounts for approximately 1/3rd of the total global deaths suggesting 
the severity of CVDs [33]. When the CVDs are co-occurring with other physiological ail-
ments, the situation becomes even worse. One of the exciting aspects of CVDs is the high 
rate of mortalities observed in low and middle-income countries, thus possess potential 
socio-economic hazards [34]. Several risk factors such as physical inactivity, the occur-
rence of other pathophysiological conditions, poor hygienic conditions, inappropriate diet 
systems are highly responsible for aggravating the consequences of CVDs. Hence, the ad-
vent of CVDs infers a more significant challenge to the scientific community to develop 
novel strategies to overcome the health hazards and preservation of humankind from 
such health consequences (Figure 2). 
 
Figure 2. Schematic representation of different types of cardiovascular diseases (CVDs), the risk factors associated with 
the occurrence of CVDs and the common pathophysiological symptoms involved in CVDs. 
The conventional therapeutic strategy for vascular diseases includes administering 
small drug molecules through oral, parenteral, intravenous, and intra-arterial routes. 
However, systemic side effects, rapid drug clearance, drug instability, and non-targeted 
localization limits the applications of drug molecules. Apart from administering drug 
molecules, invasive procedures such as angioplasty, atherectomy, stenting, bypass graft-
ing are commonly employed to treat vascular diseases. However, the lack of bioimaging 
modalities limits their usefulness. In this context, alternative, non-invasive, target-ori-
ented, and bioimaging assisted modalities could be considered to manage vascular dis-
eases [35]. 
Nanoparticles as Theranostic Agents for Cardiovascular Diseases 
Since the advent of nanotechnological concepts and their intervention into biological 
issues, a long-range of spatially designed nanomaterials are being considered for wide-
spread applications in various fields. The emergence of nanobiotechnology has specifi-
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cally revolutionized the biomedical sectors and characteristically improve the current un-
derstanding of various pathophysiological conditions and their guided therapeutic 
measures. A number of factors such as high surface plasmon resonance (SPR), high sur-
face to volume ratio, tunability, biocompatibility, optical and magnetic properties are re-
sponsible for their influence in disease diagnosis and as localized therapeutics [36]. Inor-
ganic nanoparticles (metal and metal oxide-based nanoparticles), organic nanoparticles 
(Polymer-based nanoparticles), carbon-based and lipid-based nanomaterials exhibited 
promising attributes as multifunctional theranostic agents. The concept of nan-
otheranostics has gained recent recognition to implement the management of CVDs and 
neurological disorders after being highly affirmed in its recognition in cancer therapeutics 
[37]. 
3. Nanotheranostics for Atherosclerosis 
3.1. Atherosclerosis: An Overview 
Atherosclerosis refers to the pathophysiological conditions where the medium and 
large arteries are significantly affected due to spatial deposition of various materials such 
as lipoproteins (particularly cholesterol), immune cells (circulating monocytes), proin-
flammatory factors (i.e., macrophages and T-cells), degraded extracellular matrix compo-
nents and necrotic products. Atherosclerosis is considered to be the primary cause of 
chronic CVDs, including coronary heart disease, cerebrovascular disease, and peripheral 
arterial disease [38–40]. Atherosclerosis is characterized by a series of physiological 
events, including endothelial dysfunction, inflammatory responses, cell proliferation, lip-
oprotein deposition, vascular remodeling, and finally, plaque formation [41]. The patho-
physiological conditions associated with atherosclerosis are highly influenced by the mac-
rophages as their migration, activation, infiltration and proliferation characteristically 
promote the formation of inflammated atherosclerotic plaques. The atherosclerotic 
plaques are composed of lipids (mainly cholesterol followed by phospholipids), inflam-
matory cells, smooth muscle cells, connective tissue (including collagen and elastic fibers), 
thrombi and calcium deposits [42]. The inflammation is due to the secretion of several 
proteases and tissue factors under macrophages’ influence. Hence, macrophage-targeted 
therapeutics are considered to be promising in minimizing the inflammatory responses 
and the degradation of atherosclerotic plaques [39]. The design and development of 
theranostic nanomaterials for the management of atherosclerosis depend upon several 
physiological markers. One of the exciting biomarkers to target atherosclerotic plaques is 
fibrin, which characteristically facilitates sensitive detection during plaque formation. In 
addition to fibrin, αvβ3 integrin is also considered a unique biomarker as it is associated 
with the process of angiogenesis and transiently expressed when the endothelial layer 
remains physiologically intact. Hence, the therapeutic measures centered around target-
ing these important physiological markers when spatially designed nanomaterials are be-
ing considered as theranostic materials [43]. Looking into the conventional therapeutics 
for atherosclerosis, it was observed that drug candidates targeting atherosclerosis promot-
ing factors such as hypertension and dyslipidemias are regularly being considered. In ad-
dition, the importance of inflammatory responses during atherosclerotic plaque for-
mation, anti-inflammatory drugs are also being administered to treat atherosclerosis [38]. 
Additionally, the conventional therapeutics also include FDA-approved statins i.e. β-Hy-
droxy β-methylglutaryl-CoA (HMG-CoA) reductase inhibitors), fibrates, nicotinic acid 
and ezetimibe [44].  
3.2. Nano-based Platforms for Diagnosis and Treatment of Atherosclerosis 
The concept of nano-based platforms represents the basis for multifaceted applica-
tions such as diagnosis of pathophysiological conditions of any particular disease and 
critically modulating the therapeutic measures from a single platform. The nano-based 
theranostics are regularly used in cancer diagnosis and therapies. The promising 
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theranostic aspects of nano-based cancer therapy platforms gained considerable interest 
in the last few years for targeted image-guided treatment of other chronic diseases, in-
cluding CVDs. Spatially designed nano-systems are considered the highly decorated ar-
senal to treat atherosclerosis [36] (Figure 3). As per the recent trends, FDA-approved na-
noparticles such as PLGA, hyaluronic acid, and liposomes gained considerable attention 
for atherosclerosis treatment. These nanomaterials tend to imitate high-density lipopro-
teins (HDLs), which are known for anti-atherogenic properties. 
Similarly, polymeric nanoparticles and HDL mimicking nanoparticles have also 
gained the center of attraction for determining the bioimaging and therapeutic modalities 
in managing atherosclerosis [45]. In the quest for novel nanotherapeutics for diagnosis 
and treatment of atherosclerosis, a biologically active natural polymer, hyaluronic acid 
(HA), was exploited for nanoparticle synthesis. The amine-functionalized hyaluronic 
acid-nanoparticles (HA-NPs) labeled with a fluorescent or radionuclide agent effectively 
promote macrophages’ logistic uptake and mediate ablation of atherosclerotic plaques. 
The fluorescent agent presence served as a potential contrasting agent and provided a 
platform for bioimaging modalities [46]. In the last decade, a significant contribution has 
been made in the field of designing and developing novel nano-based theranostic agents 
for the diagnosis and therapy of atherosclerotic plaques through the common platform 
(Table 1). 
Table 1. List of notable theranostic nanoparticles designed and developed for the diagnosis and therapy of atherosclerosis, 
an important factor of cardiovascular diseases (CVDs) since the 2010s. 
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Figure 3. An overview of the pathophysiological events associated with the induction of atherosclerosis, therapeutic bi-
omarkers for diagnosis and treatment of atherosclerosis and the advantages associated with nano-based theranostic tools 
for the management of CVDs. 
Angiogenesis is a standard process during atherosclerosis growth and progression. 
Hence, anti-angiogenic factors and drug moieties are being considered therapeutic mod-
ules for atherosclerosis treatment. For more specificity, the anti-angiogenic drug, per-
fluorocarbon, was designed into the phospholipid bilayer-based nano-emulsions target-
ing the αvβ3 integrin and thus served as multimodal nanocomplexes for diagnosis and 
therapy [43]. In addition, inorganic nanoparticles, magnetic nanoparticles, polymeric na-
noparticles, and micelles are also considered promising nanocarriers for target-oriented 
delivery of a wide range of drug moieties, antibodies and photosensitizers. One of the 
interesting aspects of considering nanomaterials as theranostic agents for atherosclerotic 
therapeutics is their tunability to utilize various bioimaging modalities to diagnose dis-
ease progression [57]. Since the nano-based platforms provide a wide range of diagnostic 
imaging and therapeutic applications for atherosclerosis, an array of nano-based carriers 
are actively exploited for vascular disease management. 
The characteristic physicochemical properties such as high SPR, absorption capabil-
ity, optical properties, biocompatibility and ability to bind to targeting agents provide the 
functional attributes of gold nanoparticles (AuNPs) as bioimaging and therapeutic mod-
ules. The high SPR effect of AuNPs is being deployed for photothermal therapy (PTT), 
where AuNPs promote macrophage depletion by transducing the light energy into heat 
in atherosclerotic conditions. Inorganic nanoparticles are being actively employed for PTT 
utilizing spatial wavelength of near-infrared laser light, leading to intracellular hyperther-
mia. The use of gold nanorods and silica-gold hybrid nanoparticles was reported to work 
in tandem with PTT and induce a series of physiological events, including the macro-
phages apoptosis and reduced risk of cardiovascular mortality by decreasing the total ath-
eroma volume, respectively [58]. AuNPs also act as promising carriers for photosensitiz-
ers during photodynamic therapy (PDT). AuNPs facilitate the binding of photosensitizers 
to the atherosclerotic plaques and mediates the plaques’ depletion by generating reactive 
oxygen species (ROS) when irradiated. The surface modification and functionalization of 
AuNPs further improved the therapeutic measures under consideration. The PEGylated 
aminolevulinic acid-coated AuNPs also exhibited a significant effect on plaque macro-
phage content [41]. 
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Similarly, mesoporous silica-coated conversion nanoparticles are being exploited as 
a platform for photosensitizers to trigger NIR-mediated PDT. Under NIR irradiation’s in-
fluence, a significant decrease in the intracellular lipids and an increased influx of choles-
terol efflux were observed, suggesting an antagonistic effect on atherosclerosis [59,60]. In 
the early 2000s, a new therapeutic strategy evolved, known as plasmonic PTT (PPTT), 
which is considered for targeting the atherosclerotic plaque formation by exploiting the 
infrared properties of noble metal nanoparticles (specifically AuNPs) under the guidance 
of magnetic resonance [61]. The spatially designed multifunctional AuNPs could bring a 
paradigm shift in the current therapeutic intervention concept for CVDs, including ather-
osclerosis. The involvement of AuNPs as contrasting agents for early diagnosis through 
CT imaging exhibited high-density resolution of the deep tissues under consideration and 
could be influential in atherosclerosis bioimaging [58].  
Paramagnetic nanoparticles are highly effective in the diagnosis and treatment of 
atherosclerosis. Anti-angiogenic factors could be encapsulated into the magnetically ac-
tive nanomaterials for effective clearance of atherosclerotic plaques associated with angi-
ogenesis. The optical properties also facilitate the bioimaging module, which further ena-
bles therapeutic measures under consideration [42]. Other inorganic nanoparticles, in-
cluding iron oxide nanoparticles (IONPs), are also being exploited for the management of 
atherosclerosis. When iron oxide nanoparticles are used combined with conventional bi-
oimaging modalities (i.e., MRI and PET scan), highly sensitive and highly spatial resolu-
tion were observed, suggesting their candidature for bioimaging modalities [58]. Since 
IONPs exhibit superparamagnetic properties (SPIONs), they could be exploited as alter-
native contrasting agents for conventional diagnostic imaging techniques, including MRI. 
The ease of synthesis, ease of biofunctionalization and chemical modification are the func-
tional attributes of SPIONs depicting their candidature for bioimaging and therapeutics 
[62]. SPIONS-based multimodal imaging technique enables atherosclerosis diagnosis as it 
could be exploited to image the pathophysiological conditions within the macrophages 
and other biological moieties with high specificity [40]. Besides being used as bioimaging 
agents, SPIONS also provided platforms for encapsulation of drug moieties of interest, 
followed by guiding the drug moieties towards the target sites under the influence of 
magnetic fields [40]. The attributes such as surface functionalization and modification fa-
cilitate selective targeting and image-guided therapies. As discussed earlier, macrophages 
are considered a promising target when designing nanotheranostic platforms to manage 
atherosclerosis. In this context, cross-linked dextran-coated iron oxide nanoparticles 
(CLIO-NPs) were prepared in a combination of a chlorine-based photosensitizer, i.e., 
meso-tetra (m-hydroxyphenyl) chlorin (THPC) for macrophage targeted atherosclerosis 
therapeutics under the influence of near-infrared light. Based upon the promising results, 
it could be suggested that nanocarriers-based PDT may provide an added advantage to 
deep tissue imaging and therapy [47,63]. 
Based upon the characteristic physicochemical properties such as biocompatibility, 
stability, high drug payload, sustained-release efficacy, localized drug targeting, and rel-
atively low toxicity, the lipid-based nanoparticles, including liposomes, are being actively 
exploited for diagnosis and therapies of atherosclerosis. Since the liposomal carrier could 
incorporate both hydrophilic and hydrophobic drug molecules, encapsulation of drug 
moieties and antibiotics of different specificity are encapsulated into the liposomal carrier 
for diagnosis and/or therapy for atherosclerosis [57,64]. When combined with an anti-pro-
liferative agent, paclitaxel, earlier, cholesterol-rich nano-emulsions exhibited a promising 
reduction in the size of the atherosclerotic lesions [65]. The exploration of novel hybrid 
nanomaterials for diagnosis and therapeutics gained recent recognition as the combina-
tion of spatial physicochemical attributes provided new dimensions to the current under-
standing of therapeutic measures. In this context, synthetic polymer-lipid hybrid nano-
particles were designed for the treatment of atherosclerosis. The spatially designed hybrid 
nanomaterials specifically target multiple target sites due to the combination of dual-re-
sponsive nanomaterials. Besides, the hybrid nanomaterials also allowed encapsulation of 
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high SPR exhibiting inorganic nanoparticles (AuNPs, SPIONs, and QDs) as a potential 
contrasting agent that facilitates the bioimaging modalities of the highly designed hybrid 
nanomaterials. Thus, hybrid nanomaterials could provide a new basis for atherosclerosis 
prognosis and therapeutic management [66]. Earlier, spatially designed solid-lipid nano-
particles (SLN) conjugated with a contrasting agent (iron oxide nanoparticles) and pros-
tacyclin exhibited a reduction in platelet aggregation and thus could be instrumental in 
atherosclerosis theranostics [56]. 
Understanding the pathophysiology of atherosclerosis, it was observed that CC 
chemokine receptor 2 (CCR2) tends to be highly expressed on inflammatory cells and in 
the atherosclerotic plaques. Hence, targeting the transcriptomic profiling of CCR2 could 
pave the way for effective therapeutics in atherosclerosis management. In this context, 
self-assembled specific peptide-based nanoparticles were spatially designed to target 
CCR2. Since CCR2 is associated with atherosclerosis progression, the high affinity to-
wards CCR2 could provide the platform for both diagnosis and therapeutics of athero-
sclerosis. The spatially designed peptide-based nanoparticles inhibited the expression of 
CCR2 by mediating a cascade of events such as ameliorating the monocyte migration and 
modulating the inflammatory response of IL-1β [67]. It is evident from pathophysiological 
studies, low-density lipoproteins (LDLs) naturally accumulate in the atherosclerotic 
plaques and associate with the proteoglycans and remnant ROS. As a result, an increased 
accumulation of macrophages occurs at the plaque site mediated through a number of 
receptors such as Toll-like receptors (TLR4), lectin-like receptors (LOX-R) and scavenger 
receptor A (SRA). As the LDLs primarily involve in atherosclerotic progression, squalene 
(precursor for cholesterol) was employed as a biomimetic carrier for specific interaction 
with the LDLs. When the biomimetic carrier is conjugated with specific fluorescent mole-
cules, it could be utilized for bioimaging and image-guided therapy for atherosclerosis 
[68]. 
In recent times, considerable interest is being laid upon using naturally derived mol-
ecules, mostly from plant sources, for therapeutic applications. Plant-based natural prod-
ucts are also observed for the synthesis of biogenic nanoparticles. Besides, plant-based 
compounds are also spatially incorporated into specific nanocarriers as effective thera-
peutics. In this context, plant-based compounds loaded into nanocarriers also gained con-
siderable attention for the treatment of vascular diseases, including CVDs, as it is evident 
that inorganic nanoparticles are being actively used as contrast agents and therapeutic 
drug delivery. Recently, curcumin, a bioactive compound, was incorporated into titanium 
oxide nanoparticles and conjugated with the MCP-1 antibody. The resulting nanoplat-
forms exhibited promising attributes as contrast agents for MRI and could be utilized for 
the early diagnosis of atherosclerosis [69]. 
4. Nanotheranostics for Aneurysm 
4.1. Aneurysm: An Overview 
The pathophysiological condition of ‘aneurysm’ is inferred to the enlargement/ bulg-
ing/ distention of the artery due to the weakening of the arterial wall and proved to be 
associated with fatal complications when ruptured at a later stage of development. As per 
the recent trends and reports from the Centers for Disease Control and Prevention (CDC), 
an aortic aneurysm causes the death of approximately 25,000 people every year in the 
United States. The excessive deposition of fats and cholesterol, high blood pressure, obe-
sity, smoking, age, and family history of heart diseases are the common risk factors asso-
ciated with aneurysms. Based upon the localization of arterial distention, the aneurysm is 
categorized into the aortic aneurysm (linked to the main aorta carrying blood from left 
ventricles of the heart through the chest and abdomen), cerebral aneurysm/intracranial 
aneurysm (arteries supplying blood to the brain) and peripheral aneurysm (occurs at pe-
ripheral arteries). The aneurysm associated with the heart is further categorized into a 
more pronounced abdominal aortic aneurysm (AAA) and lesser-known thoracic aortic 
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aneurysm (TAA). Both aortic and cerebral aneurysms were highly fatal and could lead to 
lethal conditions due to stroke. Among the different types of aneurysms, AAA gained 
considerable attention as it is the primary cause of the high mortality rate and morbidity 
in older adults. When ruptured, the fatality of AAAs could be observed from several path-
ophysiological events such as neovascularization, increased reactive oxygen species 
(ROS) generation, apoptosis of vascular smooth muscles, and degradation of aortic lamel-
lae and infiltration of inflammatory cells [70]. The above-mentioned pathophysiological 
events lead to severe medical complications such as thromboembolism, rupture of the 
aorta, severe chest and/or back pain, angina (leading to myocardial ischemia and heart 
attack) and severe headache due to subarachnoid hemorrhage (SAH). Since the occur-
rence of AAAs is associated with a high prevalence of CVDs, including myocardial infarc-
tion, stroke, ischemic heart disease and heart failure, the rate of cardiovascular mortality 
also increases at an alarming rate when the patients were diagnosed with AAAs [71]. 
As per the therapeutic procedures, mechanical and invasive intervention proved to 
be effective in treating aneurysms. The invasive procedures involve either open surgery 
to fit a synthetic or stent-graft or the endovascular repair using stent-graft surgery. For 
open-type AAA repair, the abdomen is incised to expose the aorta, followed by applying 
a graft into the aneurysm site. Meanwhile, in the endovascular method, an endovascular 
graft is inserted through the incision using a catheter followed by the graft’s repositioning 
to seal the aneurysm. Open surgery is generally associated with perioperative mortality 
and morbidity. On the other hand, the endovascular repair mechanism is generally con-
tributing 60–70% success rate as this mechanism is also associated with several complica-
tions such as the requirement of reintervention due to reperfusion (bleeding around the 
graft), blockage of the stent, nerve damage, kidney failure and erectile dysfunction [70]. 
Thus, it is essential to develop alternative non-invasive therapeutic measures for the treat-
ment of aneurysms. 
4.2. Nano-Based Platforms for Diagnosis and Treatment of Aneurysm  
Based upon the severity of aneurysms and limitations associated with the conven-
tional invasive procedures, highly sufficient and alternative non-invasive approaches for 
diagnosis and therapeutics are the need of the hour. As the multifaceted nanoplatforms 
exhibit promising physicochemical properties, they are being considered effective 
theranostic agents. The exploitation of nano-based platforms improved the early diagno-
sis due to the spatial optical and magnetic properties. It provided a basis for encapsulating 
drug moieties of interest for targeted delivery to manage aneurysms (Figure 4). It is 
known that AAAs leads to the upregulation of matrix metalloprotease resulting in the 
degradation of elastin and elastin matrix of the aortic wall and thus associated with pro-
gressive loss of elasticity. 
Targeting the regulation of matrix metalloprotease and delaying the growth and pro-
gression of AAAs are viable methodologies for therapeutics. Though doxycycline (tetra-
cycline-based antibiotic) is clinically reported for slowing the AAAs progression, relative 
systemic side effects and promoting the inhibition of elastin matrix deposition limit its 
widespread therapeutic application [72,73]. In this context, surface-functionalized 
doxycycline-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles were designed to 
overcome the limitations associated with doxycycline. The spatially designed, biocompat-
ible doxycycline loaded PLGA nanoparticles critically enhanced aortic uptake, followed 
by improved elastin binding. The sustained release of doxycycline from the nanoplat-
forms progressively down-regulated the matrix metalloprotease activity [72]. The encap-
sulation of superparamagnetic iron oxide nanoparticles (SPIONs) into the spatially de-
signed doxycycline-loaded PLGA nanoparticles further improved the elastic matrix dep-
osition at the target sites by inhibiting the specific matrix metalloprotease-2 and matrix 
metalloprotease-9 activities. Thus, incorporating additional and detailed modalities into 
the designed nanoplatforms could improve therapeutic measures for AAAs [74]. 




Figure 4. Schematic overview of aortic aneurysms (AA), an important aspect of CVDs and the potential biomarkers con-
sidered as a putative target for the diagnosis and therapeutic measures for the management of aneurysms. 
The localized delivery of doxycycline from PLGA based nanomaterials improved the 
elastogenesis and strongly inhibited the matrix metalloprotease activity [75]. The charac-
teristic therapeutic effect of sustained delivery of doxycycline is achieved through inhib-
iting the expression and phosphorylation of the regulatory protein, c-Jun-N-terminal ki-
nase 2 (JNK 2) and consequent upregulation of transforming growth factor-beta (TGF-β1) 
[76]. In a subsequent study, doxycycline loaded into cationic amphiphile modified submi-
cron particles were surface modified with a specific antibody, which acts upon the lyso-
somal protease, cathepsin K. Since cathepsin K tend to overexpressed during the growth 
and progression of AAAs, the spatially designed platforms not only controlled the sus-
tained release of doxycycline but also specifically act upon the cathepsin K and thus con-
trols the regulation of its expression profile. Thus, the designed particles achieved bi-
modal therapeutics by maintaining the elastogenic properties of aortic walls without sys-
temic side effects upon release of doxycycline and, on the other hand exhibiting the anti-
proteolytic activity by down-regulating the expression of cathepsin K [73]. 
For therapeutic intervention in targeting the AAAs, it is equally important to diag-
nose the growth and pathophysiological changes. Conventional anatomical imaging tech-
niques such as Computed tomography (CT), magnetic resonance imaging (MRI), nuclear 
imaging and optical imaging are widely used for diagnosis. Similarly, coronary artery 
aneurysms, coronary angiography, intravascular ultrasound, CT angiography, echocardi-
ography and coronary MR angiography are regularly used for diagnosis [77]. The limita-
tions associated with CT imaging are systemic toxicity (irrational use of iodine and/or 
gadolinium-based contrasting agents) and the inability to provide exact pathological in-
formation about extracellular matrix degradation, which further aggravate the conditions. 
In this context, optically active, relatively low toxic and exhibiting high absorption co-
efficient gold nanoparticles (AuNPs) could be considered as promising alternative con-
trasting agents for CT imaging. Due to the tunability for surface modification associated 
with AuNPs, thus improved the sustained drug delivery at the target sites. The polyeth-
ylene glycol (PEG) modified AuNPs not only characteristically improved the imaging 
quality with in-depth analysis of pathophysiological conditions related to AAAs but also 
critically reduce the use of contrasting agents, thus minimizing the relative toxicity [78]. 
Since elastin is considered an important biomarker in the progression of aortic aneurysms, 
spatially designed nanoparticles targeting the elastin protein could facilitate a new dimen-
sion to current knowledge of diagnosis and therapy of AAAs. In this context, elastin-tar-
geted AuNPs were formulated as a potential tool for diagnosing aneurysms and thus me-
diating the appropriate therapeutic approach [79]. 
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For early diagnosis and treatment of aortic aneurysms, lipid-based nanomaterials are 
considered to be highly effective. These nanomaterials can encapsulate both hydrophilic 
and hydrophobic drug molecules with a high drug payload. In addition, ease of surface 
functionalization, controlled release profile, biocompatibility, and localized drug target-
ing are the most important lipid-based nanoparticles’ attributes. Paramagnetic/fluores-
cent micellar nanomaterials functionalized with collagen-binding protein (CAN-35) ex-
hibited promising aspects as diagnostic tools to visualize fibrotic response in the aortic 
wall associated with aneurysms [80]. Recently, FDA-approved statin (pitavastatin) was 
encapsulated into liposomes and developed a target recognizing liposomal nanocarrier 
by conjugating the drug-containing liposomes biotinylated bio-nanocapsules. The hybrid 
nanomaterials enable the binding of the nanocarriers to the targeted graft followed by 
sustained release of the loaded drug, which significantly down-regulated the matrix met-
alloprotease expression. Hence, the nanohybrid system could be considered as promising 
therapeutic machinery for aortic aneurysms [81]. The exciting aspect of selecting nano-
based platforms for disease diagnosis and therapy is their ability to accumulate different 
kinds of drug moieties of interest. It was observed that aortic aneurysms are associated 
with several pathophysiological events, including vascular calcification and degradation 
of the elastic lamina. In order to achieve dual-target specific activities, the nanomaterials 
were designed to conjugate with particular materials such as ethylene diamine tetraacetic 
acid (EDTA) and pentagalloyl glucose (PGG) for dual-responsive events such as mineral 
deposition minimization and elastic lamina restoration, respectively. The spatially de-
signed nanomaterials were observed to control macrophages’ accumulation, reduction of 
matrix metalloprotease activity, vascular calcification, and elastic lamina degeneration 
[82]. 
5. Nanotheranostics for Myocardial infarction 
5.1. Myocardial infarction: An Overview 
Myocardial infarction refers to the obstruction of coronary arteries resulting in pro-
longed ischemia and loss of cardiomyocytes, vascular cells and interstitial cells [83]. My-
ocardial infarction or cardiopathy becomes a severe public health issue as acute myocar-
dial infarction is associated with a high mortality rate and morbidity [84]. The increased 
myocardial infarction incidence results from the imbalance between the oxygen supply to 
the myocardial tissues concerning the oxygen demand to the myocardial tissue [85,86]. 
Myocardial infarction is commonly known as a heart attack. A portion of the heart did not 
receive a fresh supply of oxygen due to a coronary artery blockage. Since the coronary 
arteries’ function lies in collecting newly oxygenated blood to the myocardium, the de-
prived supply of oxygen to the myocardium leads to the death of myocardial cells (called 
infarct). The condition of hypercholesterolemia, abnormally low level of good cholesterol 
(HDL), high blood pressure, diabetic disease, obesity, and lack of regular physical activity 
are the risk factors associated with myocardial infarction (heart attack). The symptoms of 
myocardial infarction include chest pain, irregular heart beating, weakness, fatigue, pro-
fuse sweating, breathlessness, nausea, and vomiting [87]. Since the mortality and morbid-
ity rates are comparatively higher in myocardial infarction, early diagnosis and proper 
therapeutic measures should be undertaken. 
5.2. Nano-based Platforms for Diagnosis and Treatment of Myocardial infarction 
In the quest for novel non-invasive techniques for early diagnosis and treatment of 
myocardial infarctions, the conventional bioimaging modalities were developed in com-
bination with precise nanomaterials. Nanomaterials’ physicochemical and optical prop-
erties are considered as prolific contrasting agents for bioimaging modalities with im-
proved resolution. In this regard, pH-sensitive albumin nanocomposites in conjugation 
with manganese dioxide (MnO2) motifs were engineered. The novel nanocomposites ex-
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hibited a multi-fold increase in the relaxation of myocardial infarction. The nanocompo-
sites were spatially designed to accumulate in the heart’s ischemic tissue, from where they 
were uptake by macrophages. Once the nanocomposites were uptake, Mn2+ was released 
and used as a biomarker for high precision bioimaging [84]. The pathophysiological con-
ditions of myocardial infarction are generally induced by myocardial ischemia and hy-
poxia, which ultimately trigger ROS production. The spatial over-production of ROS fur-
ther leads to reduced expression of the glutathione level. Hence, detecting the glutathione 
level could pave the way for diagnosing ischemic heart disease and myocardial infarction. 
In this regard, carbon dots based ultrasensitive biosensors were developed to detect glu-
tathione levels, which correlates with the pathophysiology of myocardial infarction. The 
sensitivity of carbon dots-based biosensors was improved by incorporating silver nano-
particles (AgNPs), mesoporous silica and graphene oxide. Among the conjugated nano-
materials-based biosensors, carbon dots in association with mesoporous silica exhibited a 
promising ultra-sensing ability. Thus, this concept could facilitate the early detection of 
myocardial infarction and therefore provide necessary inputs for further therapeutics [88] 
(Figure 5). 
 
Figure 5. A schematic overview of the pathophysiological risk factors associated with myocardial infarction (heart attack), 
important healthcare settings in CVDs and the potential pathophysiological targets for early diagnosis and therapy of 
myocardial infarction using nanotheranostic platforms. 
Myoglobin is a crucial cardiac biomarker for early detection and diagnosis of myo-
cardial infarction as it released into the bloodstream once there is an incidence of cardiac 
muscle injury. Hence, monitoring the myoglobin level could facilitate the early detection 
and appropriate therapeutic measures for myocardial infarction. In this context, Mn-
doped zinc oxide nanoparticles (Mn-ZnO NPs) were spatially designed to detect early 
signs of acute myocardial infarction by monitoring myoglobin content. As evidenced from 
results, the engineered nanomaterials observed to detect the electrochemical changes in 
the level of myoglobin and could be considered as ultrasensitive biosensors [89]. For effi-
cient detection and diagnosis of myocardial infarction, AuNPs served as a promising con-
trasting agent for CT imaging. The conjugation of collagen adhesion into the engineered 
AuNPs strictly improved the detection of myocardial scar and ischemic injuries and facil-
itated proper therapeutic measures to be taken into consideration [90]. In an earlier study, 
the electrochemiluminescence properties of N-(aminobutyl)-N-(ethylisoluminol)-func-
tionalized gold nanoparticles (ABEI-AuNPs) and citrate-capped AuNPs were developed 
for sensitive detection of human cardiac troponin I, an important biomarker for diagnosis 
of acute myocardial infarction [91,92].  
Pharmaceutics 2021, 13, 348 15 of 24 
 
 
For the detection and monitoring of pathophysiological conditions associated with 
myocardial tissues, cardiac magnetic resonance imaging (CMR) was developed. Paramag-
netic gadolinium (Gd3+) is being actively employed as contrasting agents for CMR. As 
contrasting agents’ role critically influences the detection and monitoring of different 
pathophysiological conditions, it is essential to the quest for novel nano-based polar 
agents. In this regard, Gd-based paramagnetic quantum dots in conjugation with specific 
tripeptide were developed as contrasting agents for detecting and imaging myocardial 
neovasculature. Though Gadolinium is observed to be safe as a contrasting agent, in few 
cases, Gd-based contrasting agents’ regular use leads to severe nephrogenic systemic fi-
brosis. In this context, physiocochemical properties of various nanomaterials physiochem-
ical properties could be considered as alternative and effective contrasting agents for di-
agnosis purposes. For instance, SPIONs were reported for their ability to detect the differ-
ence between normal and infarcted myocardium due to contrasting differential measures 
[93,94]. 
Apart from being used as a potential contrasting agent for bioimaging modalities, 
AuNPs also showed promising therapeutic efficacy. Intravenously administered AuNPs 
have been shown to critically improve the isoproterenol-induced myocardial infarction 
by maintaining cardiomyocytes’ architecture and expression of endothelial nitric oxide 
(eNO) and B-cell lymphoma 2 [95]. In an earlier study, proanthocyanidin-synthesized 
AuNPs exhibited a characteristic cardioprotective effect by mitigating the isoproterenol-
induced myocardial injury [96]. The infiltration of circulating macrophages during myo-
cardial infarction pathophysiological progression is considered a potential biomarker for 
detecting diseased conditions. The utilization of SPIONs based MRI bioimaging modali-
ties as promising contrasting agents for targeting the infiltrating macrophages to diagnose 
the pathophysiological responses. The SPIONs based contrasting agents were observed to 
exhibit higher efficacy and ultra-sensitivity in detecting the macrophages, thus suggesting 
their importance in the diagnosis and therapy of myocardial infarction [97]. The clinically 
approved SPIONs (ferucarbotran) for human use exhibited improved visualization of 
macrophages in infarcted myocardial tissue and thus could be considered as a potent con-
trasting agent for MRI [98]. The widespread utilization of metal and metal oxide-based 
inorganic nanoparticles as prolific contrasting agents and drug delivery platforms gained 
considerable attention in detecting and managing CVDs. In recent times, manganese ox-
ide nanoparticles (MnO NPs) were engineered and directed to use as a contrasting agent 
for MRI bioimaging modalities for early and sensitive detection of myocardial infarction. 
The engineered MnO NPs also act as a promising drug delivery vehicle and could be in-
strumental in treating ischemic heart disease [99]. 
FDA-approved PLGA-based polymeric nanoparticles are also employed for the treat-
ment of myocardial infarction. For instance, insulin-like growth factor (IGF-1) complexed 
with PLGA nanoparticles exhibited increased retention of IGF-1 as it is important in reg-
ulating myocardial function, growth of cardiomyocytes and cardiomyocytes survival. 
When IGF-1 was exogenously supplied, when complexed with PLGA nanoparticles, in-
creased cardioprotection incidence, prevention of cardiomyocyte apoptosis, reduction in 
infarct size, and improved left ventricular incidence ejection fraction (LVEF) were ob-
served [100,101]. The therapeutic efficacy of pitavastatin-loaded PLGA nanoparticles was 
established in ischemia-reperfusion injury in the myocardium. The engineered nanopar-
ticles loaded with pitavastatin exhibited promising cardioprotective properties by induc-
ing phosphorylation of protein kinase (PI3K)/Akt pathway and inhibiting the inflamma-
tion and apoptosis of cardiomyocytes in the myocardium [102]. Lipid-based nanocarriers, 
especially liposomes, are highly influential in targeted drug delivery with high drug pay-
load and controlled release efficacy. As thrombosis is generally associated with myocar-
dial infarction’s pathophysiology, localized delivery of the thrombolytic drug, urokinase, 
could be considered to treat myocardial infarction. Liposomal vehicular nanocarriers were 
designed to encapsulate urokinase and further surface-functionalized with cyclic tripep-
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tide for targeted delivery of urokinase. The functionalization facilitates the selective bind-
ing of tripeptide to GPIIb/IIIa receptors present on the activated platelets and allows se-
lective delivery of urokinase at the target sites [103]. The use of stabilizers like polyeth-
ylene glycol (PEG) as a surface modification on liposomal nanocarriers further improved 
the circulation time and prolonged the therapeutic effect in minimizing the infarcted my-
ocardial tissues [104]. Apart from liposomes, paramagnetic micellar nanoparticles func-
tionalized with extracellular matrix metalloproteinase inducer (EMMPRIN) binding pep-
tide, AP-9 (NAP9), also designed to target the EMMPRIN, which plays a pivotal role in 
inducing matrix metalloprotease activity during ischemic conditions. Thus, targeting 
EMMPRIN could facilitate the relative repression of the metalloprotease protein expres-
sion and thereby regulate the pathophysiology of infarcted myocardium [105]. Lipid-
based nanoparticles are considered highly effective not only as diagnostic tools but also 
as therapeutic drug delivery systems for CVDs. When designed for myocardial infarction 
management, micellar nanoparticles were observed that were explicitly distributed in the 
entire infarcted area and thus facilitated the targeted delivery of therapeutic drugs. Mean-
while, liposomal nanocarriers exhibited relatively slower and restricted extravasation 
suggesting their efficacy in delivering pro-angiogenic drugs. Though both lipid-based na-
nomaterials exhibited differential functional attributes, they remain the therapeutic plat-
form for myocardial infarction [106]. 
Cardiac ischemia-induced myocardial infarction is generally associated with ele-
vated ROS and intracellular Ca2+ following the reperfusion injury leading to cell death and 
cardiac hypertrophy. In this regard, spatially designed multifunctional poly(glycidyl 
methacrylate) (PGMA) nanoparticles loaded with specific peptide (showing affinity to-
wards the alpha-interacting domain (AID) of L-type Ca2+ channel) and potent antioxidant 
molecules (curcumin/resveratrol) for combinatorial therapy. The simultaneous delivery 
of the specific peptide and antioxidant moieties allowed the reduction in the elevated level 
of ROS and Ca2+ and thus was observed to be involved in minimizing the pathophysio-
logical events associated with ischemic injuries [107]. 
6. Nanotheranostics for Angiogenesis or Regeneration 
One of the most exciting aspects of therapies associated with CVDs is the restoration 
of blood supply, as there are several instances of blood occlusion during the progression 
of CVDs. The repair of blood vessels is achieved through many inter-related physiological 
mechanisms such as angiogenesis, vasculogenesis and arteriogenesis. Angiogenesis refers 
to the restoration of blood vessels by augmenting the host angiogenic response. The pro-
cess of angiogenesis is a highly regulated mechanism involving the interplay between pro-
angiogenic and anti-angiogenic factors. The process of angiogenesis involves a sequential 
cascade of events, including activation (increased vascular permeability and detachment 
of pericytes from endothelial cells), progression (degradation of extracellular matrix and 
migration of endothelial cells), migration, differentiation and maturation [108]. 
Therapeutic angiogenesis forms the basis for revascularizing the ischemic tissues by 
promoting specific growth factors and progenitor cells [109]. Gene therapy and stem cell 
therapy are recognized in therapeutic angiogenesis and employed to improve blood flow, 
revascularization and myocardial function [110]. In addition to gene and cell-based ther-
apy, protein therapy also received recognition for therapeutic angiogenesis by the direct 
intervention of angiogenic proteins. The advantages such as tunability in systemic/local-
ized delivery, ease of systemic administration (intravenous and/or intraperitoneal) are as-
sociated with protein therapy-based angiogenesis [111]. The vascular endothelial growth 
factors (VEGFs) mediated therapeutic angiogenesis reported to treat ischemic heart dis-
ease [112]. In addition to VEGFs, fibroblast growth factors (FGFs) are also exploited for 
therapeutic angiogenesis and are administered as recombinant proteins or the genes en-
coding these proteins [113]. 
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The advent of nano-based delivery systems has revolutionized the healthcare sectors 
and showed promising aspects in the management of CVDs. Localized targeting, con-
trolled release, and increased circulation time are essential for therapeutic efficacy. In this 
regard, the factors responsible for angiogenesis also required suitable nano-based deliv-
ery systems for promoting angiogenesis. An important factor for angiogenesis is mi-
croRNA-126 (miR-126), which plays a crucial role by blocking the expression of sprouty-
related EVH1 domain-containing protein 1 (SPRED1). Since SPRED1 is known to inhibit 
the angiogenic factor, VEGF; blocking the SPRED1 is essential for maintaining the angio-
genesis. For effective control of SPRED1, miR-126 loaded PLGA nanoparticles were de-
signed. The nanoparticles allowed the localized and sustained release of miR-126 to in-
hibit SPRED1 and thus promoted angiogenesis [114]. Based on the importance of pro-an-
giogenic factors in the process of angiogenesis, deferoxamine-loaded biocompatible 
PLGA nanoparticles (DFO NPs) were designed and incorporated into the chitosan-hyalu-
ronic acid-based hydrogel. DFO NPs loaded composite hydrogel (mimicking the extracel-
lular matrix) shown to promote neovascularization by sustained delivery of deferoxamine 
[115]. Earlier, heparin-conjugated PLGA nanoparticles were reported for their role in ther-
apeutic angiogenesis. The biocompatible nanoparticles significantly promote angiogene-
sis by stimulating the angiogenic growth factors and could be considered to treat ischemic 
disease [116]. To increase the effect of nano-based delivery platforms on angiogenesis, 
lipophilic and non-steroidal anti-inflammatory drug, celecoxib was formulated with bio-
compatible hydrogel-based nano-emulsions. The spatially designed nanomaterials char-
acteristically improved angiogenesis by augmenting the limitations associated with the 
hydrophobic nature of celecoxib [117]. As angiogenesis is essential for treating ischemia 
and zinc, it is categorized as a stimulatory effect on angiogenesis; zinc-based metal epi-
gallocatechin-3-gallate (EGCG) nanocapsules were designed for the sustained release of 
zinc ions to stimulate angiogenesis. The conjugation of EGCG promotes ROS scavenging 
of inflammatory responses. The engineered metal-based polyphenol nanonetwork exhib-
ited a significant effect on the induction of endothelial cell migration and critically en-
hanced VEGF’s secretion, thereby facilitating a microenvironment for angiogenesis treat-
ment of ischemic heart disease [118]. Since nano-based platforms with the loaded drug 
moieties and angiogenic factors facilitate the process of angiogenesis, they could promote 
revascularization of ischemic heart tissues and repress the progression of tissue infarction 
[119]. 
Graphene oxide and reduced graphene oxide specifically induced angiogenesis by 
modulating the physiological level of ROS, reactive nitrogen species (RNS) and activation 
of endothelial nitric oxide synthase. PEGylated graphene oxide also promotes angiogen-
esis with reduced cytotoxic effects [120,121]. Earlier, pro-angiogenic biosynthesized 
AuNPs were designed to facilitate the process of angiogenesis. Angiogenesis, under the 
influence of biogenic AuNPs, was achieved through the activation of the Akt pathway 
and modulating the redox signaling process [122]. 
7. Limitations and Future Perspectives 
Several therapeutic drug molecules were developed in the biotechnological and 
pharmaceutical sectors, with differential functional attributes. For example, few drug moi-
eties can be used as a biomarker for diagnosis purposes, whereas other drug molecules 
exhibited therapeutic efficacy. Though an array of drug molecules is being employed to 
manage CVDs, they only temporarily delayed the progress of pathophysiological condi-
tions. Besides, the therapeutic use of these drug molecules also leads to systemic side ef-
fects. In this context, nano-based platforms proved to be a dual-responsive system where 
they could be utilized both as diagnostic and therapeutic tools from a single platform. The 
localized drug delivery and prolonged therapeutic effect due to increased circulation time 
also characteristically established the utility of nano-based media [123]. The nanotechno-
logical intervention also facilitates the diagnosis of disease prognosis and relatively asso-
ciated therapeutic strategies through a common platform. Hence, the nanoplatforms have 
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given a new dimension to design and develop smart nanotheranostic agents for disease 
diagnosis and therapeutics. Owing to the recent impact on global health issues associated 
with CVDs, theranostic nanomedicines proved to be effective in complementing conven-
tional diagnosis and therapeutic measures [32]. As evident from earlier studies, nano-
based theranostics were found to influence the prognosis of atherosclerosis, angiogenesis 
and other CVDs by sensitive detection of pathophysiological conditions and also infer 
appropriate therapeutic measures [124]. The efficacy of nanotheranostics in CVDs lies in 
the early and sensitive detection of CVDs associated with pathophysiology, controlled 
and localized drug delivery, and prolonged therapeutic effect [125]. 
Based upon the differential physicochemical properties, optical characteristics and 
magnetic behavior, engineered nanomaterials exhibited widespread functional attributes. 
No doubt, various nanomaterials as theranostics are used for different purposes; their 
specificity and efficacy are based upon the target specificity. Nanomaterials were de-
signed and engineered for multiple applications with differential advantages and disad-
vantages. One of the most important limitations of the use of engineered nanomaterials 
as next-generation nanotheranostic agents is the use of these nanoplatforms is limited to 
laboratory setup and in the preliminary stage of clinical settings. Hence, it is important to 
decipher the sustainability and prospective toxicity profile of the engineered nanomateri-
als before being considered for clinical applications [120]. Though the preclinical studies 
have established the widespread applications of theranostic nanoplatforms for the effi-
cient management of CVDs, the translational aspect of nanotheranostics to clinical 
healthcare settings remain unexplored and more intensive and integrative approach 
needs to be followed with possible toxicity profile and other regulatory issues in mind 
[126]. In addition, specific targeting of potential biomarkers, innate toxicity of different 
components associated with naotheranostic platforms, maintenance of the stability of the 
formulated nanotheranostic agents, production costs and other regulatory issues are as-
sociated with the limitations of nanotheranostic agents. Secondly, the targeted therapeutic 
mechanisms associated with theranostic nanoplatforms differ from person to person and 
thus, integrative personalized nanomedicines need to be developed for effective diagnosis 
and therapeutics of several diseases and disorders, including CVDs [127]. Apart from the 
above-mentioned parameters, ethical issues and cost-effectiveness of large-scale prepara-
tion of theranostic nanoplatforms also proved to be a challenging aspect in translating the 
experimental settings into clinical and market-oriented approaches [64]. Another limiting 
aspect of nanotheranostics in the maintenance of CVDs and other vascular diseases is that 
the majority of preclinical studies were reported from small animal models where differ-
ential anatomies of vascular diseases are observed as compared to human counterparts. 
Hence, it is important to validate the efficacy of the engineered nanotheranostic materials 
in higher animal models for clinical and potential commercial use [35]. 
8. Recent Patents Progress in Cardiovascular Therapeutics 
Considerable progress has been made in the last few decades on developing 
theranostic nanoparticles with differential formulation for multifunctional biomaterials 
for various biomedical applications and is being patented. This progress could be instru-
mental in the future for efficient management of CVDs and other diseases [128–130]. Sim-
ilarly, a considerable progress has also been made in the invention of novel biomaterials 
to manage CVDs. Recently, UV-cross-linkable gelatin methacrylate-based cardiac patch, 
impregnated with gold nano-rods with improved physicochemical characteristics (high 
surface area and improved conductivity), was patented (US20170143871 A1). In another 
recent invention, nanoparticle-based stem cell conjugates were developed and patented 
(JP5495215 B2) for treatment in the post-infarction period. For efficient detection and treat-
ment of coronary heart disease, spatially designed nanomagnetic particles were devel-
oped and patented (CN102085380A). Most recently, Chinese traditional medicine com-
bined with solid lipid nanoparticles was patented (CN103027981B) to treat coronary heart 
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disease efficiently. Though considerable progress has been made in patenting the nano-
therapeutics in diagnosing and treating CVDs, their translation into clinical settings re-
mains obscured due to stringent regulatory guidelines in developing nano-based thera-
peutics [131,132]. 
Since the engineered nanomaterials with suitable therapeutic drug moieties exhib-
ited certain advantages as well as few limitations, however, the ease of synthesis, surface 
modification, and functionalization provided new avenues to re-engineer the theranostic 
nanomaterials of particular interest to improve diagnosis and therapy efficacy. Though 
the engineered theranostic nanoparticles possess few differential limitations, the advent 
of nanotheranostics has opened a new door for a new scope and scintillating avenues for 
developing novel platforms to improve healthcare settings and minimize the nuisances of 
different pathophysiological conditions. As discussed earlier, the intervention of nan-
otheranostics has revolutionized our knowledge to tackle the problems associated with 
CVDs by complementing the available diagnostic and therapeutic tools. The increased 
incidence of nanotheranostics in biomedical sectors emerged as prolific non-invasive tech-
niques, thereby augmenting the limitations associated with traditional invasive proce-
dures to treat CVDs. No doubt, nanotheranostics constitute widespread applications for 
disease diagnosis and therapies, but it is also important to regulate these engineered 
theranostic nanoparticles’ rational use. One more interesting aspect in utilizing 
theranostic nanoparticles is the imbalance between the number of different theranostic 
agents reported for their widespread biomedical applications and the number of engi-
neered theranostic nanoparticles that cross the clinical barriers and are employed for hu-
man use. In this context, regulatory bodies should evaluate and formulate regulatory 
guidelines to transform theranostic nanoparticles’ laboratory settings to clinical settings 
followed by human consumption and/or use. 
9. Conclusions 
Technology intervention and improved healthcare settings have provided a cue to 
diagnose and develop one or other therapeutic measures for CVDs. In the development 
of novel therapeutics, the emergence of theranostic nanoparticles allows dual-responsive 
modalities to diagnose the pathophysiological conditions and provides therapeutic mo-
dalities through a single platform. The impact of nanotheranostics in cancer biology has 
provided a new dimension to design and develop novel nanotheranostics to manage other 
diseases and disorders. Though the intervention of nanotheranostics in the management 
of CVDs is a new venture in the healthcare settings, the impact observed has revolution-
ized our understanding of the pathophysiology of CVDs and interpreted appropriate 
therapeutic measures. The spatially designed theranostic nanoparticles exhibited promis-
ing influence in augmenting atherosclerosis progression, ischemic heart disease, myocar-
dial infarction, and aneurysms. Besides, the theranostic nanoparticles also tend to pro-
mote angiogenesis, which is essential for maintaining the cardiovascular apparatus’s 
health. In the last few years, the incidence of theranostic nanoparticles employed for the 
management of CVDs was increased exponentially in laboratory settings. It is essential to 
transform theranostic nanoparticles’ efficacy into clinical health settings before being con-
sidered for human use. 
Author Contributions: Conceptualization, R.P. and S.M.N.; resources, S.P.; writing—original draft 
preparation, R.P and S.P.; writing—review and editing, S.P., R.P., S.B. and S.M.N.; supervision, S.B., 
R.P. and S.M.N.; All authors have read and agreed to the published version of the manuscript. 
Funding: This research was funded by the American Heart Association (grant ID: 19IP-
LOI34730020) and the National Institutes of Health (grant ID: HL147311). 
Institutional Review Board Statement: Not applicable 
Informed Consent Statement: Not applicable 
Pharmaceutics 2021, 13, 348 20 of 24 
 
 
Data Availability Statement: No new data were created or analyzed in this study. Data sharing is 
not applicable to this article. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Bloom, D.E.; Cadarette, D. Infectious disease threats in the twenty-first century: Strengthening the global response. Front. Im-
munol. 2019, 10, 549. 
2. Kassa, M.; Grace, J. The Global Burden and Perspectives on Non-Communicable Diseases (NCDs) and the Prevention, Data 
Availability and Systems Approach of NCDs in Low-resource Countries. In Public Health in Developing Countries—Challenges 
and Opportunities. Anugwom, E.E., Awofeso, N., Eds.; Intech Open, London, UK, 2019; pp. 1–21. 
3. Zumla, A.; Rao, M.; Wallis, R.S.; Kaufmann, S.H.E.; Rustomjee, R.; Mwaba, P.; Vilaplana, C.; Yeboah-Manu, D.; Chakaya, J.; 
Ippolito, G.; et al. Host-directed therapies for infectious diseases: Current status, recent progress and future prospects. Lancet. 
Infect. Dis. 2016, 16, e47–e63. 
4. Scire, J.; Hoze, N.; Uecker, H. Aggressive and moderate drug therapy for infectious diseases? Trade-offs between different 
treatment goals at the individual and population levels. PLoS Comput. Biol. 2019, 15, e1007223. 
5. Ladner, J.T.; Grubaugh, N.D.; Pybus, O.G.; Andersen, K.G. Precision epidemiology for infectious disease control. Nat. Med. 2019, 
25, 206–211. 
6. Muthu, M.S.; Mei, L.; Feng, S.S. Nanotheranostics: Advanced nanomedicine for the integration of diagnosis and therapy. Nano-
medicines 2014, 9, 1277–1280. 
7. Kalash, R.S.; Lakshmanan, V.K.; Cho, C.S.; Park, I.K. Theranostics. In Biomaterials Nanoarchitectonics. Andrew, W., Ed.; Elsevier, 
Amsterdam, The Netherlands, 2016, pp. 197–215. 
8. Indoria, S.; Singh, V.; Hsieh, M F. Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review. Int. J. 
Pharmaceut. 2020, 582, 119314. 
9. Degrauwe, N.; Hocquelet, A.; Digklia, A.; Schaefer, N.; Denys, A.; Duran, R. Theranostics in interventional oncology: Versatile 
carriers for diagnosis and targeted image-guided minimally invasive procedures. Front. Pharmacol. 2019, 10, 450. 
10. Huang, H.; Lovell, J.F. Advanced functional nanomaterials for theranostics. Adv. Funct. Mater. 2017, 27, 1603524. 
11. Jamil, B.; Rai, M. Nanotheranostics: An emerging nanoscience. In Nanotheranostics: Applications and Limitations; Jamil, B., Rai, 
M., Eds.; Springer Nature: Berlin/Heidelberg, Germany, 2019, pp. 1–18. 
12. Jeelani, S.; Jagat Reddy, R.C.; Maheswaran, T.; Asokan, G.S.; Dany, A.; Anand, B. Theranostics: A treasured tailor for tomorrow. 
J. Pharm. Bioallied. Sci. 2014, 6, S6–S8. 
13. Kim, T.H.; Lee, S.; Chen, X. Nanotheranostics for personalized medicines. Expert. Rev. Mol. Diagn. 2013, 13, 257–269. 
14. Kaur, C.D.; Mishra, K.K.; Sahu, A.; Panik, R.; Kashyap, P.; Mishra, S.P.; Kumar, A. Theranostics: New era in nuclear medicine 
and radiopharmaceuticals. In Medical Isotopes; Naqvi, S.A.R., Imran, M.B., Ozdemir, D.I., Eds.; Intech Open, London, United 
Kingdom: 2020, pp. 1–15. 
15. Kumar, A.; Chaudhary, R.K.; Singh, R.; Singh, S.P.; Wang, S.Y.; Hoe, Z.Y.; Pan, C.T.; Shiue, Y.L.; Wei, D.Q.; Kaushik, A.C.; et al. 
Nanotheranostic applications for detection and targeting neurodegenerative diseases. Front. Neurosci. 2020, 14, 305. 
16. Sonali, M.K.V.; Singh, R.P.; Agrawal, P.; Mehata, A.K.; Datta Maroti Pawde, N.; Sonkar, R.; Muthu, M.S. Nanotheranostics: 
Emerging strategies for early diagnosis and therapy of brain cancer. Nanotheranostics 2018, 2, 70–86. 
17. Ahmadian, E.; Dizaj, S.M.; Sharifi, S.; Shahi, S.; Khalilov, R.; Eftekhari, A.; Hasanzadeh, M. The potential of nanomaterials in 
theranostics of oral squamous cell carcinoma: Recent Progress. Trend. Anal. Chem. 2019, 116, 167–176. 
18. Madamsetty, V.S.; Mukherjee, A.; Mukherjee, S. Recent trends of the bio-inspired nanoparticles in cancer theranostics. Front. 
Pharmacol. 2019, 10, 1264. 
19. Bhattarai, N.; Bhattarai, S.R. Theranostic Nanoparticles: A recent breakthrough in Nanotechnology. J. Nanomed. Nanotechnol. 
2012, 3, e114. 
20. Sharma, M.; Dube, T.; Chibh, S.; Kour, A.; Mishra, J.; Panda, J.J. Nanotheranostics, a future remedy of neurological disorders. 
Expert. Opin. Drug. Deliv. 2019, 16, 113–128. 
21. Parodi, A.; Rudzinska, M.; Leporatti, S.; Anissimov, Y.; Zamyatnin, A.A., Jr. Smart nanotheranostics responsive to pathological 
stimuli. Front. Bioeng. Biotechnol. 2020, 8, 503. 
22. Kim, H.; Beack, S.; Han, S.; Shin, M.; Lee, T.; Park, Y.; Kim, K.S.; Yetisen, A.K.; Yun, S.H.; Kwon, W.; et al. Multifunctional 
photonic nanomaterials for diagnostic, therapeutic, and theranostic applications. Adv. Mater. 2018, 30, 1701460. 
23. Patel, Kapil, D.; Singh, Rajendra, K.; Kim, H W. Carbon-based nanomaterials as an emerging platform for theranostics. Mater. 
Horiz. 2019, 6, 434. 
24. Peng, H.; Liu, X.; Wang, G.; Li, M.; Bratlie, K.M.; Cochran, K.; Wang, Q. Polymeric multifunctional nanomaterials for 
theranostics. J. Mater. Chem. B. 2015, 3, 6856–6870. 
25. Qian, C.; Chen, Y.; Feng, P.; Xiao, X.; Dong, M.; Yu, J.; Hu, Q.; Shen, Q.; Gu, Z. Conjugated polymer nanomaterials for 
theranostics. Acta. Pharmacolog. Sinica. 2017, 38, 764–781. 
26. Barras, A.; Skandrani, N.; Pisfil, M.G.; Paryzhak, S.; Dumych, T.; Haustrate, A.; Heliot, L.; Gharbi, T.; Boulahdour, H.; Lehen’Kyi, 
V.; et al. Improved photodynamic effect through encapsulation of two photosensitizers in lipid nanocapsules. J. Mater. Chem. B. 
2018, 6, 5949. 
Pharmaceutics 2021, 13, 348 21 of 24 
 
 
27. Li, L.; Wang, J.; Kong, H.; Zeng, Y.; Liu, G. Functional biomimetic nanoparticles for drug delivery and theranostic applications 
in cancer treatment. Sci. Technol. Adv. Mater. 2018, 19, 771–790. 
28. Mura, S.; Couvreur, P. Nanotheranostics for personalized medicines. Adv. Drug. Del. Rev. 2012, 64, 1394–1416. 
29. Yetisgin, A.A.; Cetinel, S.; Zuvin, M.; Kosar, A.; Kutlu, O. Therapeutic nanoparticles and their targeted delivery applications. 
Molecules. 2020, 25, 2193. 
30. Zhang, Y.; Zhang, Q.; Zhang, A.; Pan, S.; Cheng, J.; Zhi, X.; Ding, X.; Hong, L.; Zi, M.; Cui, D.; et al. Multifunctional co-loaded 
magnetic nanocapsules for enhancing targeted MR imaging and in vivo photodynamic therapy. Nanomed. Nanotechnol. Biol. 
Med. 2019, 21, 102047. 
31. Waglewska, E.; Pucek-Kaczmarek, A.; Bazylinska, U. Novel surface-modified bilosomes as functional and biocompatible 
nanocarriers of hybrid compounds. Nanomaterials 2020, 10, 2472. 
32. Singh, D.; Dilnawaz, F.; Sahoo, S K. Challenges of movingtheranostic nanomedicine into the clinic. Nanomedinces 2020, 15, 111–
114. 
33. Yusuf, S.; Joseph, P.; Rangarajan, S.; Islam, S.; Mente, A.; Hystad, P.; Brauer, M.; Kutty, V.R.; Gupta, R.; Wielgosz, A.; et al. 
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and 
low-income countries (PURE): A prospective cohort study. Lancet 2019, 395, 795–808. 
34. Gersh, Bernard, J.; Sliwa, K.; Mayosi, B.M.; Yusuf, S. The epidemic of cardiovascular disease in the developing world: Global 
implications. Eur. Heart. J. 2010, 31, 642–648. 
35. Gupta, Mukesh, K.; Lee, Y.; Boire, T.C.; Lee, J.B.; Kim, W.S.; Sung, H J. Recent strategies to design vascular theranostic nanopar-
ticles. Nanotheranostics 2017, 1, 166–177. 
36. Bejarano, J.; Navarro-Marquez, M.; Morales-Zavala, F.; Morales, J.O.; Garcia-Carvajal, I.; Araya-Fuentes, E.; Flores, Y.; Verdejo, 
H.E.; Castro, P.F.; Lavandero, S.; et al. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: 
Evolution toward prospective theranostic approaches. Theranostics 2018, 8, 4710–4732. 
37. Siafaka, P.I.; Okur, N.U.; Karantas, I.D.; Okur, M.E.; Gundogdu, E.A. Current update on nanoplatforms as therapeutic and 
diagnostic tools: A review for the materials used as nanotheranostics and imaging modalities. Asian. J. Pharmaceut. Health Sci. 
2020, doi:10.1016/j.ajps.2020.03.003. 
38. Cervadoro, A.; Palomba, R.; Vergaro, G.; Cecchi, R.; Menichetti, L.; Decuzzi, P.; Emdin, M.; Luin, S. Targeting inflammation 
with nanosized drug delivery platforms in cardiovascular diseases: Immune cell modulation in atherosclerosis. Front. Bioeng. 
Biotechnol. 2018, 6, 177. 
39. Peng, R.; Ji, H.; Jin, L.; Lin, S.; Huang, Y.; Xu, K.; Yang, Q.; Sun, D.; Wu, W. Macrophage-based therapies for atherosclerosis 
management. J. Immunol. Res. 2020, 2020, 8131754. 
40. Talev, J.; Kanwar, J R. Iron oxide nanoparticles as imaging and therapeutic agents for atherosclerosis. Semin. Thromb. Hemost. 
2020, 46, 553–562. 
41. Goncalves, K.O.; da Silva, M.N.; Sichhieri, L B.; de Oliveira Silva, F.R.; de Matos, R.A.; Courrol, L C. Aminolevulinic acid with 
gold nanoparticles: A novel theranostic agent for atherosclerosis. Analyst 2015, 140, 1974. 
42. Karagkiozaki, V.; Logothetidis, S.; Pappa, A.M. Nanomedicine for atherosclerosis: Molecular imaging and treatment. J. Biomed. 
Nanotechnol. 2015, 11, 191–210. 
43. Caruthers, S.D.; Cyrus, T.; Winter, P.M.; Wickline, S.A.; Lanza, G.M. Anti-angiogenic perfluorocarbon nanoparticles for diag-
nosis and treatment of atherosclerosis. WIREs Nanomed. Nanobiotechnol. 2009, 1, 311–323. 
44. Basnet, R.; Khadka, S.; Wang, Y.; Gupta, R. Research progress on diagnosis and treatment of atherosclerosis. Sci. Lett. 2020, 8, 
18–22. 
45. Chen, J.; Zhang, X.; Millican, R.; Creutzmann, J.E.; Martin, S.; Jun, H.W. High density lipoprotein mimicking nanoparticles for 
atherosclerosis. Nano Convergence 2020, 7, 6. 
46. Beldman, T.J.; Senders, M.L.; Alaarg, A.; Perez-Medina, C.; Tang, J.; Zhao, Y.; Fay, F.; Deichmöller, J.; Born, B.; Desclos, E.; et al. 
Hyaluronan nanoparticles selectively target plaque-associated macrophages and improve plaque stability in atherosclerosis. 
ACS Nano 2017, 11, 5785–5799. 
47. McCarthy, J.R.; Korngold, E.; Weissleder, R.; Jaffer, F A. A light-activated theranostic nanoagent for targeted macrophage abla-
tion in inflammatory atherosclerosis. Small 2010, 6, 2041–2049. 
48. Shon, S.-M.; Choi, Y.; Kim, J.-Y.; Lee, N.K.; Park, J.-Y.; Schellingerhout, D.; Kim, N.-E. Photodynamic therapy using a protease-
mediated theranostic agent reduces Cathepsin-B activity in mouse atheromata in vivo. Arterioscler Thromb Vasc Biol. 2013, 33, 
1360–1365. 
49. Qin, J.; Peng, Z.; Li, B.; Ye, K.; Zhang, Y.; Yuan, F.; Yang, X.; Huang, L.; Hu., J.; Lu, X. Gold nanorods as a theranostic platform 
for in vitro and in vivo imaging and photothermal therapy of inflammatory macrophages. Nanoscale 2015, 7, 13991–14001. 
50. Yeager, D.; Chen, Y.S.; Litovsky, S.; Emelianov, S. Intravascular photoacoustics for image-guidance and temperature monitoring 
during plasmonic photothermal therapy of atherosclerotic plaques: A feasibility study. Theranostics 2014, 4, 36–46. 
51. Kosuge, H.; Sherlock, S.P.; Kitagawa, T.; Dash, R.; Robinson, J.T.; Dai, H.; McConell, M.V. Near infrared imaging and photo-
thermal ablation of vascular inflammation using single-walled carbon nanotubes. J. Am. Heart Assoc. 2012, 1, e002568. 
52. Lobatto, M.E.; Fayad, Z.A.; Silvera, S.; Vucic, E.; Calcagno, C.; Mani, V.; Dickson, S.D.; Nicolay, K.; Banciu, M.; Schiffelers, R.M.; 
et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental athero-
sclerosis. Mol. Pharm. 2010, 7, 2020–2029. 
Pharmaceutics 2021, 13, 348 22 of 24 
 
 
53. Park, D.; Cho, Y.; Goh, S.H.; Choi, Y. Hyaluronic acid–polypyrrole nanoparticles as pH-responsive theranostics. Chem. Comm. 
2014, 50, 15014–15017. 
54. Nandwana, V.; Ryoo, S.R.; Kanthala, S.; McMahon, K.M.; Rink, J.S.; Li, Y.; Venkatraman, S.S.; Thaxton, C.S.; Dravid, V.P. High-
Density Lipoprotein-like Magnetic Nanostructures (HDL-MNS): Theranostic agents for cardiovascular disease. Chem. Mater. 
2017, 29, 2276–2282. 
55. Bagalkot, V.; Badgeley, M.A.; Kampfrath, T.; Deiuliis, J.A.; Rajagopalan, S.; Maiseyeu, A. Hybrid nanoparticles improve target-
ing to inflammatory macrophages through phagocytic signals. J. Cont. Rel. 2015, 217, 243–255. 
56. Oumzil, K.; Ramin, M.A.; Lorenzato, C.; Hemadou, A.; Laroche, J.; Jacobin-Valat, M.J.; et al. Solid lipid nanoparticles for image-
guided therapy of atherosclerosis. Bioconjug. Chem. 2016, 27, 569–575. 
57. Zhang, Y.; Koradia, A.; Kamato, D.; Popat, A.; Little, Peter, J.; Ta, Hang, T. Treatment of atherosclerotic plaque: Perspectives on 
theranostics. J. Pharm. Pharmacol. 2019, 71, 1029–1043. 
58. Dai, T.; He, W.; Yao, C.; Ma, X.; Ren, W.; Mai, Y.; Wu, A. Applications of inorganic nanoparticles in the diagnosis and therapy 
of atherosclerosis. Biomater. Sci. 2020, 8, 3784. 
59. Zhu, X.; Wang, H.; Zheng, L.; Zhong, Z.; Li, X.; Zhao, J.; Kou, J.; Jiang, Y.; Zheng, X.; Liu, Z.; et al. Upconversion nanoparticle-
mediated photodynamic therapy induces THP-1 macrophage apoptosis via ROS bursts and activation of the mitochondrial 
caspase pathway. Int. J. Nanomed. 2015, 10, 3719–3736. 
60. Han, X.B.; Li, H.X.; Jiang, Y.Q.; Wang, H.; Li, X.S.; Kou, J.Y.; Zheng, Y.H.; Liu, Z.N.; Li, H.; Li, J.; et al. Upconversion nanoparticle-
mediated photodynamic therapy induces autophagy and cholesterol efflux of macrophage-derived foam cells via ROS genera-
tion. Cell. Death. Dis. 2017, 8, e2864. 
61. Kharlamov, A.N.; Zubarev, I.V.; Shishkina, E.V.; Shur, V.Y. Nanoparticles for treatment of atherosclerosis: Challenges of plas-
monic photothernal therapy in translational studies. Future. Cardiol. 2018, 14, 109–114. 
62. Herranz, F.; Salinas, B.; Groult, H.; Pellico, J.; Lechuga-Vieco, A.V.; Bhavesh, R.; Ruiz-Cabello, J. Superparamagnetic nanoparti-
cles for atherosclerosis imaging. Nanomater. 2014, 4, 408–438. 
63. McCarthy, J.R.; Jaffer, F.A.; Weissleder, R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small 
2006, 2, 983–987. 
64. Nakhlband, A.; Eskandani, M.; Omidi, Y.; Saeedi, N.; Ghaffari, S.; Barar, J.; Garjani, A. Combating atherosclerosis with targeted 
nanomedicines: Recent advances and future prospective. BioImpacts 2018, 8, 59–75. 
65. Shiozaki, A.A.; Senra, T.; Morikawa, A.T.; Deus, D.F.; Paladino-Filho, A.T.; Pinto, I.M.F.; Maranhao, R.C. Treatment of patients 
with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles. Clinics. 2016, 71, 435–439. 
66. Banik, B.; Surnar, B.; Askins, Brett, W.; Banerjee, M.; Dhar, S. Dual-targetedsynthetic nanoparticles for cardiovascular diseases. 
ACS Appl. Mater. Interface 2020, 12, 6852–6862. 
67. Mog, B.; Asase, C.; Chaplin, A.; Gao, H.; Rajagopalan, S.; Maiseyeu, A. Nano-antagonist alleviates inflammation and allows for 
MRI of atherosclerosis. Nanotheranostics 2019, 3, 342–355. 
68. Brusini, R.; Dormont, F.; Cailleau, C.; Nicolas, V.; Peramo, A.; Varna, M.; Couvreur, P. Squalene-based nanoparticles for the 
targeting of atherosclerotic lesions. Int. J. Pharmaceut. 2020, 581, 119282. 
69. Sherin, S.; Balachandran, S.; Abraham, A. Curcumin incorporated titanium dioxide nanoparticles as MRI contrasting agents for 
the early diagnosis of atherosclerosis-rat model. Vet. Anim. Sci. 2020, 10, 100090. 
70. Cheng, J.; Zhang, R.; Li, C.; Tao, H.; Dou, Y.; Wang, Y.; Hu, H.; Zhang, J. A targeting nanotherapy for abdominal aortic aneu-
rysms. J. Am. Col. Cardiol. 2018, 72, 2591–2605. 
71. Bath, M.F.; Gokani, V.J.; Sidloff, D.A.; Jones, L.R.; Choke, E.; Sayers, R.D.; Bown, M.J. Systemic review of cardiovascular disease 
and cardiovascular death in patients with a small abdominal aortic aneurysm. Br. J. Sur. 2015, 102, 866–872. 
72. Sivaraman, B.; Ramamurthi, A. Multifunctional nanoparticles for doxycycline delivery towards localized elastic matrix stabili-
zation and regenerative repair. Acta. Biomater. 2013, 9, 6511–6525. 
73. Jennewine, B.; Fox, J.; Ramamurthi, A. Cathepsin-K targeted sub-micron particles for regenerative repair of vascular elastic 
matrix. Acta. Biomater. 2017, 52, 60–73. 
74. Sivaraman, B.; Swaminathan, G.; Moore, L.; Fox, J.; Seshadri, D.; Dahal, S.; Stoilov, I.; Zborowski, M.; Mecham, R.; Ramamurthi, 
A. Magnetically-responsive, multifunctional drug delivery nanoparticles for elastic matrix regenerative repair. Acta. Biomater. 
2017, 52, 171–186. 
75. Venkataraman, L.; Sivaraman, B.; Vaidya, P.; Ramamurthi, A. Nanoparticulate delivery of agents for induced elastogenesis in 
three-dimensional collagenous matrices. J. Tissue. Eng. Regen. Med. 2014, 10, 1041–1056. 
76. Camardo, A.; Seshadri, D.; Broekelmann, T.; Mecham, R.; Ramamurthi, A. Multifunctional, JNK-inhibiting nanotherapeutics 
for augmented elastic matrix regenerative repair in aortic aneurysms. Drug. Deliv. Transl. Res. 2018, 8, 964–984. 
77. Sherif, S.A.; Tok, O.O.; Taskoylu, O.; Goktekin, O.; Kilic, I D. Coronary artery aneurysms: A review of the epidemiology, path-
ophysiology, diagnosis, and treatment. Front. Cardiovasc. Med. 2017, 4, 24. 
78. Wang, X.; Lane, B.A.; Eberth, J.F.; Lessner, S.M.; Vyavahare, N.R. Gold nanoparticles that target degraded elastin improve im-
aging and rupture prediction in an AngII mediated mouse model of abdominal aortic aneurysm. Theranosticics 2019, 9, 4156–
4167. 
79. Lane, B.A.; Wang, X.; Lessner, S.M.; Vyavahare, N.R.; Eberth, J.F. Targeted gold nanoparticles as an indicator of mechanical 
damage in an elastase model of aortic aneurysm. Annal. Biomed. Eng. 2020, 48, 2268–2278. 
Pharmaceutics 2021, 13, 348 23 of 24 
 
 
80. Klink, A.; Heynens, J.; Herranz, B.; Lobatto, M.E.; Arias, T.; Sanders, H.M.; Strijkers, G.J.; Merkx, M.; Nicolay, K.; Fuster, V.; et 
al. In vivo Characterization of a New Abdominal Aortic Aneurysm Mouse Model with Conventional and Molecular Magnetic 
Resonance Imaging. J. Am. Coll. Cardiol. 2011, 58, 2522–2530. 
81. Yoshimura, K.; Aoki, H.; Teruyama, C.; Iijima, M.; Tsutsumi, H.; Kuroda, S.; Hamano, K. A novel hybrid drug delivery system 
for treatment of aortic aneurysms. Int. J. Mol. Sci. 2020, 21, 5538. 
82. Nosoudi, N.; Chowdhury, A.; Siclari, S.; Karamched, S.; Parasaram, V.; Parrish, J.; Gerrard, P.; Vyavahare, N. Reversal of vas-
cular calcification and aneurysms in a rat model using dual targeted therapy with EDTA and PGG-loaded nanoparticles. Nan-
otheranostics 2016, 6, 1975–1987. 
83. Hou, L.; Kim, Joseph, J.; Woo, Y.J.; Huang, N.F. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular 
disease. Am. J. Physiol. Heart Circ. Physiol. 2016, 310, H455–H465. 
84. Wang, F.; Wen, L.; Liu, J.; Peng, W.; Meng, Z.; Chen, Q.; Wang, Y.; Ke, B.; Guo, Y.; Mi, P. Albumin nanocomposites with 
MnO2/Gd2O3 motifs for precise MR imaging of acute myocardial infarction in rabbit models. Biomaterials 2020, 230, 119614. 
85. Christia, P.; Frangogiannis, N.G. Pathophysiology of acute myocardial infarction. In Advances in Myocardial Infarction Manage-
ment; Ottervanger, J.P., Ed.; Future Medicine, London, UK, 2013; pp. 34–46. 
86. Frangogiannis, N.G. Pathophysiology of myocardial infarction. Compr. Physiol. 2015, 5, 1841–1875. 
87. Lu, L.; Liu, M.; Sun, R.R.; Zheng, Y.; Zhang, P. Myocardial infarction: Symptoms and Treatments. Cell. Biochem. Biophys. 2015, 
72, 865–867. 
88. Li, Z.; Zhang, J.; Li, Y.; Zhao, S.; Zhang, P.; Zhang, Y.; Bi, J.; Liu, G.; Yue, Z. Carbon dots based photoelectrochemical sensors for 
ultrasensitive detection of glutathione and its applications in probing of myocardial infarction. Biosens. Bioelectron. 2018, 99, 251–
258. 
89. Haque, M.; Fouad, H.; Seo, H.K.; Alothman, O.Y.; Kulkarni, A.; Ansari, Z.A. Investigation of Mn doped ZnO nanoparticles 
towards ascertaining myocardial infarction through an electrochemical detection of myoglobin. IEEE Access. 2020, 8, 164678–
164692. 
90. Danila, D.; Johnson, E.; Kee, P. CT imaging of myocardial scars with collagen-targeting gold nanoparticles. Nanomedicines 2013, 
9, 1067–1076. 
91. Shen, W.; Tian, D.; Cui, H.; Yang, D.; Bian, Z. Nanoparticle-based electrochemiluminescence immunosensor with enhanced 
sensitivity for cardiac troponin I using N-(aminobutyl)-N-(ethylisoluminol)-functionalized gold nanoparticles as labels. Biosens. 
Bioelectron. 2011, 27, 18–24. 
92. Bhalla, V.; Carrara, S.; Sharma, P.; Nangia, Y.; Suri, C.R. Gold nanoparticles mediated label-free capacitance detection of cardiac 
troponin I. Sens. Acutat. B Chem. 2012, 161, 761–768. 
93. Chapon, C.; Franconi, F.; Lemaire, L.; Marescaux, L.; Legras, P.; Saint-Andre, J.P.; Denizot, B.; Le Jeune, J.J. High field magnetic 
resonance imaging evaluation of superparamagnetic iron oxide nanoparticles in a permanent rat myocardial infarction. Invest. 
Radiol. 2003, 38, 141–146. 
94. Grimaldi, A.M.; Forte, E.; Infante, T.; Cavaliere, C.; Salvatore, M.; Cademaritri, F. Future perspectives of nanoparticle-based 
contrast agents for cardiac magnetic resonance in myocardial infarction. Nanomed. Nanotechnol. Biol. Med. 2019, 17, 329–341. 
95. Ahmed, S.M.; Abdelrahman, S.A.; Salama, A E. Efficacy of gold nanoparticles against isoproterenol induced acute myocardial 
infarction in adult male albino rats. Ultrastruct. Pathol. 2017, 41, 168–185. 
96. Vinodhini, A.; Govindaraju, K.; Singaravelu, G.; Sadiq, A.M.; Kumar, V.G. Cardioprotective potential of biobased gold nano-
particles. Colloids. Surf. B. Interface. 2014, 117, 480–486. 
97. Yilmaz, A.; Dengler, M.A.; van der Kuip, H.; Yildiz, H.; Rösch, S., Klumpp, S.; Klingel, K.; Kandolf, R.; Helluy, X.; Hiller, K.H.; 
et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a 
multi-parametric cardiovascular magnetic resonance imaging approach. Eur. Heart, J. 2013a, 34, 462-475. 
98. Yilmaz, A.; Rosch, S.; Klingel, K.; Kandolf, R.; Helluy, X.; Hiller, K.H.; Jacob, P.M.; Sechtem, U. Magnetic resonance imaging 
(MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction-Preliminary results. 
Int. J. Cardiol. 2013b, 163, 175-182. 
99. Zheng, Y.; Zhang, H.; Hu, Y.; Bai, L.; Xue, J. MnO nanoparticles with potential application in magnetic resonance imaging and 
drug delivery for myocardial infarction. Int. J. Nanomed. 2018, 13, 6177–6188. 
100. Chang, M.Y.; Yang, Y.J.; Chang, C.H.; Tang, Alan, C.L.; Liao, W.Y.; Cheng, F.Y.; Yeh, C.S.; Lai, J.J.; Stayton, P.S.; Hsieh, P.C.H. 
Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J. Cont. Rel. 2013, 170, 287–294. 
101. Ferreira, Monica, P.A.; Balasubramanian, V.; Hirvonen, J.; Ruskoaho, H.; Santos, H.A. Advanced nanomedicines for the treat-
ment and diagnosis of myocardial infarction and heart failure. Curr. Drug. Target. 2015, 16, 1682–1697. 
102. Nagaoka, K.; Matoba, T.; Mao, Y.; Nakano, Y.; Ikeda, G.; Egusa, S.; Tokutome, M.; Nagahama, R.; Nakano, K.; Sunagawa, K.; et 
al. A new therapeutic modality for acute myocardial infarction: Nanoparticle-mediated delivery of pitavastatin induces cardi-
oprotection from ischemia-reperfusion injury via activation of PI3K/Akt pathway and anti-inflammation in a rat model. PLoS 
ONE. 2015, 10, e0132451. 
103. Chandarana, M.; Curtis, A.; Hoskins, C. The use of nanotechnology in cardiovascular disease. Appl. Nanosci. 2018, 8, 1607–1609. 
104. Ferreira, M.P.A.; Santos, H.A. Nanomedicines to tackle myocardial infarction: Where are we now and where we are going. 
DOSIS Farm. Aikak. 2019, 35, 290–298. 
Pharmaceutics 2021, 13, 348 24 of 24 
 
 
105. Cuadrado, I.; Piedras, M.J.G.M.; Herruzo, I.; Turpin, M.C.; Castejon, B.; Reventun, P.; Martin,A.; Saura, M.; Zamorano, J.L.; 
Zaragoza, C. 2016. EMMPRIN-Targeted Magnetic Nanoparticles for In Vivo Visualization and Regression of Acute Myocardial 
Infarction. Theranostics 2016, 6, 545–557. 
106. Paulis, L.E.; Geelen, T.; Kuhlmann, M.T.; Coolen, B.F.; Schafers, M.; Nicolay, K.; Strijkers, G.J. Distribution of lipid-based nano-
particles to infarcted myocardium with potential application for MRI-monitored drug delivery. J. Cont. Rel. 2012, 162, 276–285. 
107. Hardy, N.; Viola, H.M.; Johnstone, V.P.A.; Clemons, T.D.; Szappanos, H.C.; Singh, R.; Smith, N.M.; Iyer, K.S.; Hool, L.C. Nano-
particle-mediated dual delivery of an antioxidant and a peptide against the L-type Ca2+ channel enables simultaneous reduction 
of cardiac ischemia-reperfusion injury. ACS Nano 2015, 9, 279–289. 
108. Darweesh, R. S.; Ayoub, N.M.; Nazzal, S. Gold nanoparticles and angiogenesis: Molecular mechanisms and biomedical appli-
cations. Int. J. Nanomed. 2019, 14, 7643–7663. 
109. Deveza, L.; Choi, J.; Yang, F. Therapeutic angiogenesis for treating cardiovascular diseases. Theranostics 2012, 2, 801–814. 
110. Liao, Y.Y.; Chen, Z.Y.; Wang, Y.X.; Lin, Y.; Yang, F.; Zhou, Q L. New progress in angiogenesis therapy of cardiovascular disease 
by ultrasound targeted microbubble destruction. Biomed. Res. Int. 2014, 2014, 872984. 
111. Chu, H.; Wang, Y. Therapeutic angiogenesis: Controlled delivery of angiogenic factors. Ther. Deliv. 2012, 3, 693–714. 
112. Zachary, I.; Morgan, R.D. Therapeutic angiogenesis for cardiovascular disease: Biological context, challenges, prospects. Heart 
2011, 97, 181–189. 
113. Vale, P.R.; Losordo, D.W.; Symes, J.F.; Isner, J.M. Growth factors for therapeutic angiogenesis in cardiovascular diseases. Rev. 
Esp. Cardiol. 2001, 54, 1210–1224. 
114. Tsumaru, S.; Masumoto, H.; Minakata, K.; Izuhara, M.; Yamazaki, K.; Ikeda, T.; Ono, K.; Sakata, R.; Minatoya, K. Therapeutic 
angiogenesis by local sustained release of microRNA-126 using poly lactic-co-glycolic acid nanoparticles in murine hindlimb 
ischemia. J. Vasc. Surg. 2018, 68, 1209–1215. 
115. Vignesh, S.; Shivashanmugam, A.; Mohandas, A.; Janarthanan, R.; Iyer, S.; Nair, S.V.; Jayakumar, R. Injectable deferoxamine 
nanoparticles loaded chitosan-hyaluronic acid coacervate hydrogel for therapeutic angiogenesis. Colloids Surf. B Biointerfcae 
2018, 161, 129–138. 
116. Lian, L.; Tang, F.; Yang, J.; Liu, C.; Li, Y. Therapeutic angiogenesis of PLGA-heparin nanoparticle in mouse ischemic limb. J. 
Nanomater. 2012, 2012, 193704. 
117. Margulis, K.; Neofytou, E.A.; Beygui, R.E.; Zare, R.N. Celecoxib nanoparticles for therapeutic angiogenesis. ACS Nano 2015, 9, 
9416–9426. 
118. Chen, Z.; Duan, J.; Diao, Y.; Chen, Y.; Liang, X.; Li, H.; Miao, Y.; Gao, Q.; Gui, L.; Wang, X.; et al. ROS-responsive capsules 
engineered from EGCG-Zinc networks improve therapeutic angiogenesis in mouse limb ischemia. Bioact. Mater. 2021, 6, 1–11. 
119. Johnson, T.; Zhao, L.; Manuel, G.; Taylor, H.; Liu, D. Approaches to therapeutic angiogenesis for ischemic heart disease. J. Mol. 
Med. 2019, 97, 141–151. 
120. Mukherjee, S.; Sriram, P.; Barui, A.K.; Nethi, S.K.; Veeriah, V.; Chatterjee, S.; Suresh, K.I.; Patra, C.R. 2015. Graphene oxides 
show angiogenic properties. Adv. Healthc. Mater. 2015, 4, 1722–1732. 
121. Jeong, J.; Cho, H.J.; Choi, M.; Lee, W.S.; Chung, B.H.; Lee, J S. In vivo toxicity assessment of angiogenesis and the live distribution 
of nano-graphene oxide and its PEGylated derivatives using the developing zebrafish embryo. Carbon 2015, 93, 431–440. 
122. Nethi, S.K.; Mukherjee, S.; Veeriah, V.; Barui, A.K.; Chatterjee, S.; Patra, C R. Bioconjugated gold nanoparticles accelerate the 
growth of new blood vessels through redox signaling. Chem. Commun. 2014, 50, 14367–14370. 
123. Li, T.; Liang, W.; Xiao, X.; Qian, Y. Nanotechnology, an alternative with promising prospects and advantages for the treatment 
of cardiovascular diseases. Int. J. Nanomed. 2018, 13, 7349–7362. 
124. Deb, S.; Ghosh, K.; Shetty, S D. Nanoimaging in cardiovascular diseases: Current state of the art. Ind. J. Med. Res. 2015, 141, 285–
298. 
125. Deng, Y.; Zhang, X.; Shen, H.; He, Q.; Wu, Z.; Liao, W.; Yuan, M. Application of the nano-drug delivery system in treatment of 
cardiovascular diseases. Front. Bioeng. Biotechnol. 2020, 7, 489. 
126. Tang, J.; Lobatto, M.E.; Read, J.C.; Mieszawska, A.J.; Fayad, Z.A.; Mulder, W J M. Nanomedical theranostics in cardiovascular 
disease. Curr. Cardiovasc. Imaging Rep. 2012, 5, 19–25. 
127. Vinhas, R.; Cordeiro, M.; Carlos, FF.; Mendo, S.; Fernandes, A.; Figueiredo, S.; Baptista, P. Gold nanoparticle-based theranostics: 
Disease diagnostics and treatment using a single nanomaterial. Nanobiosens. Dis. Diagn. 2015, 4, 11–23. 
128. Perez, J.M.; Santra, S. Multimodal, Multifunctional Polymer Coated Nanoparticles. U.S. Patent No. 8,236,284, 7 August 2012. 
129. Campbell, R.B.; Sridhar, S. Magnetic Nanoplatforms for Theranostic and Multi-Modal Imaging Applications. U.S. Patent Ap-
plication 13/583,616, 5 December 2013. 
130. Satchi-Fainaro, R.; Shabat, D.; Rachel, B.L.A.U.; Epshtein, Y.; Baabur-Cohen, H.; Ferber, S.; Redy-Keisar, O.; Kisin-finfer, E. Pol-
ymeric Systems and Uses Thereof in Theranostic Applications. U.S. Patent No. 10,532,113, 14 January 2020. 
131. Lakshmanan, R.; Maulik, N. Development of next generation cardiovascular therapeutics through bio-assisted nanotechnology. 
J. Biomed. Mater. Res. B 2017, 106, 2072–2083. 
132. Fan, C.; Joshi, J.; Li, F.; Xu, B.; Khan, M.; Yang, J.; Zhu, W. Nanoparticle-mediated drug delivery for treatment of ischemic heart 
disease. Front. Bioeng. Biotechnol. 2020, 8, 687. 
